Spectrum ends development of ozarelix for benign prostatic hypertrophy
This article was originally published in Scrip
Executive Summary
Spectrum Pharmaceuticals is discontinuing the development of ozarelix for the treatment of benign prostatic hypertrophy (BPH) from late-stage trials.